A Long-Term Outcomes Study to Assess STatin Residual Ris

Project: Research project

Project Details

Description

A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia (STRENGTH)
StatusActive
Effective start/end date2/1/162/28/21

Funding

  • AstraZeneca

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.